Cipla has launched Afrezza (insulin human) Inhalation Powder in India. Afrezza is rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy. The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus. The company had obtained regulatory approval for the exclusive distribution and marketing of Afrezza from Central Drugs Standard Control Organisation (CDSCO) late last year.
Afrezza, which is created and manufactured by MannKind Corporation (MannKind) USA, dissolves rapidly upon oral inhalation and begins lowering blood glucose within around 12 minutes, closely mirroring the body’s natural insulin response. By offering a needle-free, rapid-acting alternative to daily prandial injections, it is designed to support better adherence and enable quicker glycemic control for adults with both type 1 and type 2 diabetes mellitus. This differentiated delivery system also helps address the emotional and practical barriers that often lead patients to delay or discontinue insulin therapy, which is a need that leading healthcare experts continue to highlight as critical in strengthening diabetes care.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: